NSRX insider buying
Nasus Pharma Ltd
Every qualifying open-market purchase of NSRX reported to the SEC on Form 4, parsed directly from the filings and linked back to the source on EDGAR. No buying cluster — two or more distinct insiders inside a rolling window — has been detected in NSRX yet; if one forms, it appears here (and hits our alert subscribers in real time).
All notable open-market buys in NSRX
Every open-market Form 4 purchase, newest first. Click an insider to see their full buying record across companies.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Mar 31, 2026 | Director, Chief Executive Officer | 15,000 | $2.04 | $30.6K | SEC ↗ |
NSRX insider buying — FAQ
- Are insiders buying NSRX stock?
- 1 insider has bought NSRX (Nasus Pharma Ltd) on the open market, most recently on Apr 1, 2026. No cluster buy — two or more distinct insiders within a rolling window — has been detected yet.
- How much NSRX stock have insiders bought?
- Insiders have bought a combined $30.6K of NSRX across 1 open-market purchase, based on SEC Form 4 filings.
- What is an insider cluster buy in NSRX?
- A cluster buy is two or more distinct Nasus Pharma Ltd insiders — officers, directors, or 10% owners — each buying NSRX on the open market within a rolling window. None has been detected in NSRX yet.
- Where does this NSRX insider trading data come from?
- Every figure is parsed directly from SEC Form 4 filings on EDGAR, and each purchase on this page links back to its original filing document.
How we track insider buying in NSRX
We continuously poll SEC EDGAR for new Form 4 filings and parse every open-market purchase (transaction code P). A cluster is recorded when two or more distinct insiders — officers, directors, or 10% owners — each buy NSRX within a rolling window. We track clusters at every company size, from micro-caps to mega-caps. Every figure on this page traces back to an official filing; open any row to jump straight to the source document. What counts as a cluster buy?
This page is informational and reflects public filing data. It is not investment advice or a recommendation regarding NSRX.